- New research indicates that weight-loss medications, specifically GLP-1RA drugs, may alleviate migraine pain and reduce asthma symptoms.
- A study presented at the European Congress On Obesity found that women using Wegovy for weight management experienced a 7 per cent reduction in prescriptions for triptan-class migraine medication.
- Separately, another study revealed that individuals prescribed GLP-1 drugs for obesity or type 2 diabetes saw a 26 per cent fall in asthma exacerbations and a 14 per cent drop in reliever inhaler use.
- Experts suggest that the weight loss achieved with these medications is a significant factor, as it reduces the pro-inflammatory state linked to excess fatty tissue.
- These findings contribute to a growing body of evidence highlighting the potential therapeutic benefits of GLP-1RA drugs beyond their primary use for weight loss.
IN FULL
